Page last updated: 2024-08-23

simvastatin and Muscle Disorders

simvastatin has been researched along with Muscle Disorders in 146 studies

Research

Studies (146)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (0.68)	18.7374
1990's	16 (10.96)	18.2507
2000's	47 (32.19)	29.6817
2010's	69 (47.26)	24.3611
2020's	13 (8.90)	2.80

Authors

Authors	Studies
Asada, M; Bando, T; Chuma, M; Goda, M; Hamano, H; Ishizawa, K; Izawa-Ishizawa, Y; Kondo, Y; Miyata, K; Nakamoto, A; Niimura, T; Okada, N; Takechi, K; Tasaki, Y; Yagi, K; Yanagawa, H; Yoshioka, T; Zamami, Y	1
Lindsay, C; Musgaard, M; Russell, AJ; Sitsapesan, R	1
Huang, M; Li, Y; Prayson, RA	1
Carrasco, M; Maureira, A; Tapia, JC; Valdebenito-Maturana, B; Valdebenito-Maturana, F	1
Blazing, MA; Cannon, CP; Giugliano, RP; Lokhnygina, Y; Mitchel, YB; Musliner, TA; Nanna, MG; Navar, AM; White, JA	1
Gong, L; Guo, L; Han, F; Liu, H; Liu, L; Lv, Y; Ren, L; Wan, Z; Xu, B; Xuan, L; Yan, Y; Yang, S; Zhang, J; Zhang, W	1
Isermann, B; Laufs, U	1
Armitage, J; Baigent, C; Bowman, L; Bulbulia, R; Chen, F; Collins, R; Haynes, R; Hopewell, JC; Landray, MJ; Lathrop, M; Li, J; Offer, A; Parish, S	1
Chen, J; Li, P; Meng, L; Wang, L; Yang, H; Zheng, ZG; Zhu, L	1
Kelsey, MD; Newby, LK	1
Bai, WW; Dong, B; Fu, CN; Guo, T; Li, P; Liu, C; Song, JW; Song, ZP; Wang, QW; Wang, SX	1
Abdelsalam, RM; Abo-Zalam, HB; El-Denshary, ES; Hamzawy, MA; Khalil, IA; Khattab, MM	1
Dagda, RK; Moschetti, A; Ryan, RO	1
Barson, DJ; Blank, ML; Parkin, L; Sharples, KJ	1
El-Adeeb, N; Elmasry, A; Ghalwash, M	1
Carrasco-Ortega, O; Correa-Ramirez, M; Flores-Unzueta, S; Galaviz-Hernandez, C; Guerrero-Romero, F; Lares-Assef, I; Marchat, LA; Sosa-Macias, M	1
Li, W; Li, X; Sun, S; Xu, X; Zhao, Z	1
Chen, SQ; Cui, YM; Hu, K; Ma, LY; Mu, GY; Xiang, Q; Xie, QF; Zhang, XD; Zhang, Z	1
Fenning, AS; Irwin, JC; Ryan, KR; Vella, RK	1
Advani, S; Brunette, CA; Hau, C; MacMullen, L; Majahalme, N; Miller, SJ; Vassy, JL; Zimolzak, AJ	1
Christopher-Stine, L; Isackson, PJ; Kitzmiller, JP; Luzum, JA; Ma, C; Nguyen, LM; Ochs-Balcom, HM; Peltier, W; Tarnopolsky, M; Vladutiu, GD; Weisman, M; Wortmann, RL	1
Chan, JCM; Ng, MH; Tomlinson, B; Wong, RSM	1
Aschmann, HE; Kaufmann, M; Puhan, MA; Yebyo, HG	1
Bevington, A; Brunskill, NJ; Essid, SM	1
Abdul Rahman, H; Ahmad, Z; C Thambiah, S; Chew, BH; Hasan, S; Meor Anuar Shuhaili, MFR; Samsudin, IN; Stanslas, J	1
Ahmed, EA; Ali, MF; Hareedy, MS	1
Carroll, R; Tayal, U	1
Armitage, J; Brown, CD; Chasman, DI; Chen, YD; Collins, R; Engelhardt, BE; Feng, Q; Hopewell, JC; Howie, B; Krauss, RM; Mangravite, LM; Mecham, BH; Medina, MW; Naidoo, D; Nickerson, DA; Parish, S; Ridker, PM; Rieder, MJ; Rotter, JI; Shim, H; Smith, JD; Stephens, M; Wilke, RA	1
Bal, IB; Onur, R; Sara, Y; Severcan, F; Simsek Ozek, N	1
Kasbekar, N; Prom, R; Spinler, SA; Umscheid, CA	1
Ching, JK; Ju, JS; Margeta, M; Pittman, SK; Weihl, CC	1
Ballard, KD; Thompson, PD	1
Voora, D	1
Heckman, K; Kellick, K; Mergenhagen, K; Ott, M; Rubin, LM	1
Austin, MA; Canestaro, WJ; Thummel, KE	1
Caudle, KE; Cooper-DeHoff, RM; Feng, Q; Gong, L; Haidar, CE; Johnson, SG; Klein, TE; Krauss, RM; Maxwell, WD; McLeod, HL; Niemi, M; Ramsey, LB; Roden, DM; Voora, D; Wadelius, M; Wilke, RA	1
Bis, JC; Brody, JA; Floyd, JS; Heckbert, SR; Psaty, BM; Rice, K	1
Alfirevic, A; Carr, DF; Chinoy, H; Johnson, R; Pirmohamed, M; van Staa, T	1
Engelhardt, BE; Krauss, RM; Mangravite, LM; Stephens, M	1
Lindelof, M; Skovbølling, SL	1
Ghushchyan, V; Nair, K; Saseen, JJ; Tuchscherer, RM	1
Aarons, L; Dickinson, G; Galetin, A; Guo, Y; Hall, S; Rostami-Hodjegan, A; Tsamandouras, N	1
Kassardjian, CD; Milone, M; Tian, X; Vladutiu, G; Wong, LJ	1
Gee, RH; Johnston, JD; Malia, JM; Plant, KE; Plant, NJ; Spinks, JN	1
Jiang, Y; Li, Y; Liu, Y; Lou, Y; Pang, H; Wang, L; Zhang, J; Zhou, Y	1
Bonifacio, A; Bouitbir, J; Krähenbühl, S; Sanvee, GM	1
Adámková, V; Češka, R; Dlouhá, D; Hrubá, P; Hubáček, JA; Viklický, O; Vrablík, M; Zlatohlavek, L	1
Hou, Q; Li, L; Li, S; Li, Y; Sun, X; Tian, H	1
Ding, HJ; Ong, SG	1
Koon, CM; Lau, CB; Ng, CF; Tomlinson, B; Wat, E; Wong, EC	1
Gao, ZY; Guo, M; Kou, N; Qu, H; Shi, DZ; Wu, HT; Zhang, Y	1
Barrett, DA; Bruce, KD; de Moor, CH; Eckel, RH; Gershkovich, P; Lee, JB; Sungelo, M; Taha, DA; Zgair, A	1
Belousova, ES; Mikashinovich, ZI; Sarkisyan, OG	1
Abd El-Hakeem, EE; Almazlom, SA; Alsayyad, AJ; Kaki, AM	1
Picksak, G; Rasche-Schürmann, CC; Stichtenoth, DO	1
Braathen, P; Molden, E; Skovlund, E	1
Nakamura, Y	1
Armitage, J; Bowman, L; Collins, R; Gut, I; Heath, S; Lathrop, M; Link, E; Matsuda, F; Parish, S	1
Balík, M; Chochola, M; Horejs, J; Linhart, A; Lubanda, JC; Prskavec, T; Semrád, M; Skalicka, L; Varejka, P	1
Smith, A; Wians, F; Wu, AH	1
Burman, KD; Lando, HM	1
Constantin-Teodosiu, D; Greenhaff, PL; Mallinson, JE; Sidaway, J; Westwood, FR	1
de Carvalho, M; Evangelista, T; Ferro, J; Pereira, P	1
Isackson, PJ; Vladutiu, GD	1
Mitka, M	1
Abel, T; Fehér, J	1
Azuma, CT; Marsden, AM; Orton, TC; Scott, RC; Sidaway, J; Wang, Y; Westwood, FR	1
Onur, R; Sara, Y; Severcan, F; Simsek Ozek, N	1
Armitage, J; Bowman, L; Collins, R; Parish, S; Tobert, J	1
Damian, MS; Duncan, AJ; Hargreaves, IP; Heales, SJ; Land, JM	1
Dybała, A; Grzywa-Celińska, A; Mosiewicz, J; Myśliński, W	1
Ali, S; Ginsburg, GS; Reed, CR; Salisbury, BA; Shah, SH; Spasojevic, I; Voora, D	1
Backes, JM; Howard, PA; Moriarty, PM; Ruisinger, JF	1
Brecht, K; Krähenbühl, S; Lüscher, B; Mullen, PJ; Scharnagl, H	1
Daly, AK	1
Simon, HB	2
Beckey, C; Hough, A; Karimi, S; Parra, D	1
Frey, O	1
Brunham, LR; Carleton, BC; Carter, C; Hayden, MR; Hovingh, GK; Jukema, JW; Kastelein, JJ; Lansberg, PJ; Miao, F; Ross, CJ; Stalenhoef, AF; Visscher, H; Zhang, L	1
Hu, M; Mak, VW; Tomlinson, B	2
Dendramis, G	1
Arazi, HC; Caroli, C; Di Girolamo, G; Giorgi, MA	1
Colman, E; Egan, A	1
Crook, MA; Fung, EC	1
Anderson, EJ; Bamman, MM; Cortright, RN; Kane, DA; Kwak, HB; Lee, NS; Lin, CT; Neufer, PD; Thalacker-Mercer, A	1
Anderson, T; Boden, WE; Chaitman, BR; Desvignes-Nickens, P; Koprowicz, K; McBride, R; Probstfield, JL; Teo, K; Weintraub, W	1
Feng, GW; Li, YP; Ren, XW; Shang, WJ; Yang, WH; Zeng, ZS; Zhang, LR	1
Teramoto, T	1
Chad, DA; David, WS; Hedley-Whyte, ET; Kambadakone, A	1
Semple, SJ	1
Carrell, DS; Floyd, JS; Heckbert, SR; Psaty, BM; Weiss, NS	1
Cooper-Dehoff, RM; Feng, Q; Gong, L; Johnson, SG; Klein, TE; Krauss, RM; Maxwell, WD; McLeod, HL; Niemi, M; Ramsey, LB; Roden, DM; Voora, D; Wadelius, M; Wilke, RA	1
Callaghan, JT; Duke, JD; Flockhart, DA; Hall, SD; Han, X; Jin, Y; Karnik, SD; Li, L; Li, X; Overhage, MJ; Quinney, SK; Strother, RM; Subhadarshini, A; Wang, Z	1
Chan, SQ; Oh, DH; Wilson, AM	1
De Almeida, P; De Godoi, V; Frigo, L; Leal-Junior, EC; Leonardo, PS; Lopes-Martins, RÁ; Pallotta, RC; Rossi, RP; Tomazoni, SS	1
Constantin-Teodosiu, D; Davies, WJ; Glaves, PD; Greenhaff, PL; Mallinson, JE; Martin, EA; Sidaway, JE; Westwood, FR	1
Barber, GR; Barron, MA; Golightly, LK; Page, RL	1
Bannykh, S; England, JD; Gray, NL; Haas, RH; Hathaway, S; Kimura, BJ; Phillips, PS; Vladutiu, GD	1
Sacks, FM	1
Rogge, N	1
Baker, SK; Goodwin, S; Sur, M; Tarnopolsky, MA	1
Cartwright, MS; Donofrio, PD; Jeffery, DR; Nuss, GR	1
Battisti, WP; Brady, WE; Grundy, SM; Palmisano, J; Vega, GL; Yuan, Z	1
Hermus, AR; Lammens, M; van Engelen, BG; Voermans, NC; Wevers, RA	1
McKenney, JM	1
Henriksen, OA; Lindal, S; Trøseid, M	1
Kilkki, E; Kivistö, KT; Niemi, M; Soininen, K; Strandberg, T	1
Baker, SK; Tarnopolsky, MA	1
Guthrie, RM	1
Junni, P; Katajamaa, M; Laaksonen, R; Lehtimäki, T; Lütjohann, D; Oresic, M; Päivä, H; Saarinen, L; Seppänen-Laakso, T; Smet, J; Soini, J; Sysi-Aho, M; Van Coster, R	1
Fabian, V; Knezevic, W; Mastaglia, FL; Needham, M; Panegyres, P; Zilko, P	1
Flach, LA; Weffald, LA	1
Baldassarre, D; Calabresi, L; Mombelli, G; Palmi, I; Sirtori, CR; Zuccaro, P	1
Molden, E; Westergren, T	1
Boltan, DD; Bouffard, JP; Khetan, A; Lachar, W; Roberts, WC	1
Dande, A; Holford, TR; Kocherla, M; Ruaño, G; Seip, RL; Smith, A; Sorokin, A; Thompson, PD; Windemuth, A; Wu, AH	1
Florkowski, CM; Frampton, CM; George, PM; McEwan, RG; Molyneux, SL; Scott, RS; Young, JM	1
Galiana, J; Marchán, E; Montés, I; Pato, S	1
al-Jubouri, MA; Briston, PG; Chinn, RH; Sinclair, D; Young, RM	1
Day, AP; Stansbie, D	1
Fukami, M; Fukushige, J; Kogure, Y; Maeda, N; Ogawa, T; Shimada, Y; Tsujita, Y	1
Ichikawa, M; Matsuyama, K; Nakai, A; Nishikata, M; Uchida, T	1
Isley, W; Rajeshawari, M; Tal, A	1
Dabroś, W; Dudek, D; Stachura, J; Wicher-Muniak, E; Zmudka, K	1
Fujiyama, J; Higuchi, I; Kuriyama, M; Nakagawa, H; Nakahara, K; Osame, M; Sonoda, Y; Yoshidome, H	1
Dietz, BL; Oberg, KC	1
Gudnason, V; Heath, KE; Humphries, SE; Seed, M	1
Lupattelli, G; Palumbo, B; Sinzinger, H	1
Lan, W; Tomlinson, B	1
Bottorff, M; Worz, CR	1
Goyal, RK; Udawat, H	1
Buirma, RJ; de Sauvage Nolting, PR; Hutten, BA; Kastelein, JJ	1
Arimura, K; Higuchi, I; Kuriyama, M; Nagado, T; Nagata, K; Nakagawa, M; Nakahara, K; Osame, M; Yoshidome, H	1
Eydelloth, RS; Germershausen, JI; Grossman, SJ; MacDonald, JS; Schwartz, MS; Smith, PF; Stubbs, RJ	1
Eydelloth, RS; Germershausen, JI; Grossman, SJ; Kari, PH; MacDonald, JS; Schwartz, MS; Smith, PF; Stubbs, RJ; Vyas, KP	1
De Liege, P; Gambert, P; Laurent, A; Lecoz, P; Legrand, A; Mikol, J; Peynet, J; Warnet, A	1
England, JD; Stewart, PM; Viles, A; Walsh, JC	1
Walker, JF	1

Reviews

18 review(s) available for simvastatin and Muscle Disorders

Article	Year
Association Between Statin Use and Daptomycin-related Musculoskeletal Adverse Events: A Mixed Approach Combining a Meta-analysis and a Disproportionality Analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 10-12, Volume: 75, Issue:8 Topics: Adverse Drug Reaction Reporting Systems; Atorvastatin; Daptomycin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Rhabdomyolysis; Rosuvastatin Calcium; Simvastatin; United States; United States Food and Drug Administration	2022
Genvoya-Associated and Simvastatin-Associated Noninflammatory and Nonautoimmune Myopathy: A Case Report and Literature Review. Journal of clinical neuromuscular disease, 2022, Dec-01, Volume: 24, Issue:2 Topics: Creatine Kinase; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; Humans; Muscular Diseases; Simvastatin	2022
Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. The pharmacogenomics journal, 2018, Volume: 18, Issue:6 Topics: Aged; Female; Gene Frequency; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Pharmacogenetics; Pharmacogenomic Variants; Polymorphism, Genetic; Pyridines; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Simvastatin	2018
Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. American heart journal, 2019, Volume: 210 Topics: Atorvastatin; Cardiovascular Diseases; Cause of Death; Chemical and Drug Induced Liver Injury; Double-Blind Method; Fluvastatin; Headache; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Lovastatin; Middle Aged; Muscular Diseases; Nausea; Neoplasms; Network Meta-Analysis; Placebos; Pravastatin; Randomized Controlled Trials as Topic; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Withholding Treatment	2019
Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review. Genetics in medicine : official journal of the American College of Medical Genetics, 2014, Volume: 16, Issue:11 Topics: Amidinotransferases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Genetic Variation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Muscular Diseases; Neoplasm Proteins; Organic Anion Transporters; Simvastatin	2014
Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case-Control Studies. Medicine, 2015, Volume: 94, Issue:37 Topics: Case-Control Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Muscular Diseases; Organic Anion Transporters; Polymorphism, Genetic; Simvastatin	2015
Does simvastatin cause more myotoxicity compared with other statins? The Annals of pharmacotherapy, 2009, Volume: 43, Issue:12 Topics: Clinical Trials as Topic; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Dyslipidemias; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Rhabdomyolysis; Risk Factors; Simvastatin	2009
Genome-wide association studies in pharmacogenomics. Nature reviews. Genetics, 2010, Volume: 11, Issue:4 Topics: Anticoagulants; Aryl Hydrocarbon Hydroxylases; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP2C9; Drug-Related Side Effects and Adverse Reactions; Floxacillin; Genome-Wide Association Study; Humans; Interferon-alpha; Mixed Function Oxygenases; Muscular Diseases; Pharmacogenetics; Platelet Aggregation Inhibitors; Simvastatin; Vitamin K Epoxide Reductases	2010
[Interindividual differences in the response to statin therapy and gene polymorphisms related to myopathy during statin therapy]. Giornale italiano di cardiologia (2006), 2011, Volume: 12, Issue:3 Topics: Alleles; Chromosomes, Human, Pair 12; Confidence Intervals; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Liver-Specific Organic Anion Transporter 1; Muscular Diseases; Organic Anion Transporters; Polymorphism, Single Nucleotide; Simvastatin	2011
Pharmacogenomics and adverse drug reactions: the case of statins. Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:10 Topics: Genetic Markers; Genome-Wide Association Study; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver-Specific Organic Anion Transporter 1; Muscular Diseases; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Genetic; Simvastatin	2011
New simvastatin dosing recommendations. The Medical letter on drugs and therapeutics, 2011, Aug-25, Volume: 53, Issue:1370 Topics: Animals; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Randomized Controlled Trials as Topic; Simvastatin; United States; United States Food and Drug Administration	2011
Pitavastatin: clinical effects from the LIVES Study. Atherosclerosis. Supplements, 2011, Volume: 12, Issue:3 Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase IV as Topic; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Glomerular Filtration Rate; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kidney Diseases; Multicenter Studies as Topic; Muscular Diseases; Prospective Studies; Pyrroles; Quinolines; Risk; Simvastatin; Treatment Outcome; Triglycerides	2011
Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks. The American journal of cardiology, 2005, Aug-22, Volume: 96, Issue:4A Topics: Allylamine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Colesevelam Hydrochloride; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Muscular Diseases; Niacin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2005
How safe is aggressive statin therapy? Progress in cardiovascular nursing, 2006,Summer, Volume: 21, Issue:3 Topics: Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Muscular Diseases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2006
[Interaction risk with statin switch]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2007, Feb-15, Volume: 127, Issue:4 Topics: Anticholesteremic Agents; Anticoagulants; Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Diltiazem; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Hemorrhages; Muscular Diseases; Pyrroles; Risk Factors; Simvastatin; Warfarin	2007
[Toxic myopathies related to the administration of hypolipidemic agents: are the drugs the only things responsible?]. Revista clinica espanola, 1995, Volume: 195, Issue:9 Topics: Adult; Aged; Bezafibrate; Delayed-Action Preparations; Drug Therapy, Combination; Female; Humans; Hypolipidemic Agents; Lovastatin; Male; Muscular Diseases; Simvastatin	1995
The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins. Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:7 Topics: Aged; Clinical Trials as Topic; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diltiazem; Drug Interactions; Enzyme Inhibitors; Female; Guidelines as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Isoenzymes; Itraconazole; Lovastatin; Male; Middle Aged; Muscular Diseases; Pravastatin; Rhabdomyolysis; Simvastatin	2001
HMG CoA reductase inhibitors. Current clinical experience. Drugs, 1988, Volume: 36 Suppl 3 Topics: Eye Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Muscular Diseases; Simvastatin	1988

Trials

13 trial(s) available for simvastatin and Muscle Disorders

Article	Year
Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin. Journal of the American College of Cardiology, 2020, 02-25, Volume: 75, Issue:7 Topics: Anticholesteremic Agents; Ezetimibe, Simvastatin Drug Combination; Humans; Muscular Diseases; Simvastatin	2020
The Integrating Pharmacogenetics in Clinical Care (I-PICC) Study: Protocol for a point-of-care randomized controlled trial of statin pharmacogenetics in primary care. Contemporary clinical trials, 2018, Volume: 75 Topics: Adult; Aged; Atherosclerosis; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Pharmacogenomic Testing; Point-of-Care Systems; Precision Medicine; Primary Health Care; Primary Prevention; Secondary Prevention; Simvastatin	2018
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. European heart journal, 2013, Volume: 34, Issue:17 Topics: Arterial Occlusive Diseases; Chemical and Drug Induced Liver Injury; Death, Sudden, Cardiac; Delayed-Action Preparations; Drug Therapy, Combination; Female; Humans; Hypolipidemic Agents; Indoles; Male; Middle Aged; Muscular Diseases; Myocardial Infarction; Myocardial Reperfusion; Niacin; Simvastatin; Stroke	2013
Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach. Pharmaceutical research, 2015, Volume: 32, Issue:6 Topics: Activation, Metabolic; Biological Availability; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Healthy Volunteers; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver-Specific Organic Anion Transporter 1; Models, Biological; Muscle, Skeletal; Muscular Diseases; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Genetic; Reproducibility of Results; Simvastatin; Tissue Distribution	2015
SLCO1B1 variants and statin-induced myopathy--a genomewide study. The New England journal of medicine, 2008, Aug-21, Volume: 359, Issue:8 Topics: Aged; Arterial Occlusive Diseases; Chromosomes, Human, Pair 12; Diabetes Mellitus; Female; Genetic Markers; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Myocardial Infarction; Organic Anion Transporters; Polymorphism, Single Nucleotide; Risk; Simvastatin	2008
Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people. BMC clinical pharmacology, 2009, Mar-31, Volume: 9 Topics: Aged; Anticholesteremic Agents; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Incidence; Liver; Middle Aged; Muscles; Muscular Diseases; Patient Compliance; Placebos; Risk Factors; Simvastatin; Treatment Outcome	2009
The SLCO1B15 genetic variant is associated with statin-induced side effects. Journal of the American College of Cardiology, 2009, Oct-20, Volume: 54, Issue:17* Topics: Aged; Atorvastatin; Creatine Kinase; Female; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Organic Anion Transporters; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Simvastatin	2009
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. The New England journal of medicine, 2011, Dec-15, Volume: 365, Issue:24 Topics: Aged; Atherosclerosis; Brain Ischemia; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Muscular Diseases; Niacin; Proportional Hazards Models; Simvastatin; Treatment Failure; Triglycerides	2011
Statin-associated myopathy with normal creatine kinase levels. Annals of internal medicine, 2002, Oct-01, Volume: 137, Issue:7 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biopsy; Creatine Kinase; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Muscular Diseases; Pain; Pyrroles; Simvastatin	2002
Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). The American journal of cardiology, 2005, Feb-15, Volume: 95, Issue:4 Topics: Adult; Aged; Alanine Transaminase; Apolipoproteins; Aspartate Aminotransferases; Double-Blind Method; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Muscular Diseases; Simvastatin; Treatment Outcome; Triglycerides	2005
A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PloS one, 2006, Dec-20, Volume: 1 Topics: Atorvastatin; Biomarkers; Computational Biology; Gene Expression; Gene Expression Profiling; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Muscle, Skeletal; Muscular Diseases; Pyrroles; Simvastatin; Systems Biology	2006
Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. The American journal of cardiology, 2007, Nov-01, Volume: 100, Issue:9 Topics: Coenzymes; Double-Blind Method; Drug Tolerance; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Pilot Projects; Simvastatin; Ubiquinone; Vitamins	2007
Two-year efficacy and safety of simvastatin 80 mg in familial hypercholesterolemia (the Examination of Probands and Relatives in Statin Studies With Familial Hypercholesterolemia [ExPRESS FH]). The American journal of cardiology, 2002, Jul-15, Volume: 90, Issue:2 Topics: Anticholesteremic Agents; Apolipoproteins; Creatine Kinase; Female; Follow-Up Studies; Humans; Hyperlipoproteinemia Type II; Lipoproteins; Liver Function Tests; Male; Middle Aged; Muscular Diseases; Simvastatin; Time Factors; Transaminases; Treatment Outcome; Triglycerides	2002

Other Studies

115 other study(ies) available for simvastatin and Muscle Disorders

Article	Year
Statin activation of skeletal ryanodine receptors (RyR1) is a class effect but separable from HMG-CoA reductase inhibition. British journal of pharmacology, 2022, Volume: 179, Issue:21 Topics: Acyl Coenzyme A; Animals; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Muscle, Skeletal; Muscular Diseases; Rabbits; Ryanodine; Ryanodine Receptor Calcium Release Channel; Sheep; Simvastatin	2022
Activation of Transposable Elements in Human Skeletal Muscle Fibers upon Statin Treatment. International journal of molecular sciences, 2022, Dec-23, Volume: 24, Issue:1 Topics: Cholesterol; DNA Transposable Elements; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle Fibers, Skeletal; Muscle, Skeletal; Muscular Diseases; Rosuvastatin Calcium; Simvastatin	2022
Vitamin D supplementation rescues simvastatin induced myopathy in mice via improving mitochondrial cristae shape. Toxicology and applied pharmacology, 2020, 08-15, Volume: 401 Topics: Animals; Dietary Supplements; Energy Metabolism; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred C57BL; Mitochondria; Mitochondrial Membranes; Muscular Diseases; Random Allocation; Simvastatin; Vitamin D	2020
Statin intolerance: myths and facts. European heart journal, 2020, 09-14, Volume: 41, Issue:35 Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscles; Muscular Diseases; Risk Factors; Simvastatin	2020
Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom. European heart journal, 2020, 09-14, Volume: 41, Issue:35 Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Muscles; Muscular Diseases; Risk Factors; Simvastatin	2020
Statins induce skeletal muscle atrophy via GGPP depletion-dependent myostatin overexpression in skeletal muscle and brown adipose tissue. Cell biology and toxicology, 2021, Volume: 37, Issue:3 Topics: Adipose Tissue, Brown; Animals; Forkhead Box Protein O1; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon Regulatory Factors; Mice; Muscle, Skeletal; Muscular Atrophy; Muscular Diseases; Myostatin; Polyisoprenyl Phosphates; Simvastatin	2021
In patients at high CV risk receiving simvastatin, the Myopathy Risk Score predicted statin-related myopathy. Annals of internal medicine, 2020, 12-15, Volume: 173, Issue:12 Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscles; Muscular Diseases; Risk Factors; Simvastatin	2020
Excessive expression of miR-1a by statin causes skeletal injury through targeting mitogen-activated protein kinase kinase kinase 1. Aging, 2021, 04-16, Volume: 13, Issue:8 Topics: Animals; Apoptosis; Cells, Cultured; Disease Models, Animal; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; MAP Kinase Kinase Kinase 1; Mice; Mice, Knockout, ApoE; MicroRNAs; Muscle Fibers, Skeletal; Muscular Diseases; Physical Conditioning, Animal; Primary Cell Culture; RNA, Small Interfering; Simvastatin; Up-Regulation	2021
Therapeutic advancement of simvastatin-loaded solid lipid nanoparticles (SV-SLNs) in treatment of hyperlipidemia and attenuating hepatotoxicity, myopathy and apoptosis: Comprehensive study. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 139 Topics: Animals; Apoptosis; Biological Availability; Chemical and Drug Induced Liver Injury; Drug Carriers; Drug Delivery Systems; Hyperlipidemias; Lipids; Male; Muscular Diseases; Nanoparticles; Particle Size; Rats; Rats, Wistar; Simvastatin	2021
Coenzyme Q nanodisks counteract the effect of statins on C2C12 myotubes. Nanomedicine : nanotechnology, biology, and medicine, 2021, Volume: 37 Topics: Animals; Ataxia; Cell Line; Cell Survival; Heart Failure; Humans; Mice; Mitochondria; Mitochondrial Diseases; Muscle Fibers, Skeletal; Muscle Weakness; Muscular Diseases; Nanocomposites; Oxygen Consumption; Simvastatin; Ubiquinone	2021
Simvastatin dose and acute kidney injury without concurrent serious muscle injury: A nationwide nested case-control study. PloS one, 2017, Volume: 12, Issue:7 Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Case-Control Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Odds Ratio; Risk Factors; Simvastatin	2017
Effect of L-carnitine on the skeletal muscle contractility in simvastatin-induced myopathy in rats. Journal of basic and clinical physiology and pharmacology, 2018, 09-25, Volume: 29, Issue:5 Topics: Animals; Carnitine; Cholesterol; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle Contraction; Muscle, Skeletal; Muscular Diseases; Oxidative Stress; Rats; Rats, Wistar; Simvastatin	2018
Simvastatin-related myopathy in shift workers: a report of two cases. Drug metabolism and personalized therapy, 2018, 09-25, Volume: 33, Issue:3 Topics: Adult; Alleles; Humans; Hypolipidemic Agents; Liver-Specific Organic Anion Transporter 1; Male; Muscular Diseases; Simvastatin	2018
The Association between Genetic Polymorphisms and Simvastatin-Induced Myopathy: A Narrative Synthesis of Evidence. Drug research, 2019, Volume: 69, Issue:4 Topics: Aged; Alleles; Case-Control Studies; Cohort Studies; Female; Gene Frequency; Genetic Markers; Genotype; Humans; Male; Middle Aged; Muscular Diseases; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic; Simvastatin	2019
Validation of a clinically-relevant rodent model of statin-associated muscle symptoms for use in pharmacological studies. Toxicology and applied pharmacology, 2018, 12-01, Volume: 360 Topics: Animals; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle Proteins; Muscle, Skeletal; Muscular Diseases; Rats; Rats, Wistar; Reproducibility of Results; Rodentia; Simvastatin	2018
Clinical features related to statin-associated muscle symptoms. Muscle & nerve, 2019, Volume: 59, Issue:5 Topics: Aged; Atorvastatin; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Logistic Models; Lovastatin; Male; Medical History Taking; Middle Aged; Muscle Weakness; Muscular Diseases; Myalgia; Obesity; Odds Ratio; Pravastatin; Retrospective Studies; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Smoking; White People	2019
A case of simvastatin-induced myopathy with SLCO1B1 genetic predisposition and co-ingestion of linagliptin and Stevia rebaudiana. Journal of clinical pharmacy and therapeutics, 2019, Volume: 44, Issue:3 Topics: Aged; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Genetic Predisposition to Disease; Herb-Drug Interactions; Humans; Linagliptin; Liver-Specific Organic Anion Transporter 1; Male; Muscular Diseases; Polymorphism, Single Nucleotide; Simvastatin; Stevia	2019
Proinsulin C-Peptide Enhances Cell Survival and Protects against Simvastatin-Induced Myotoxicity in L6 Rat Myoblasts. International journal of molecular sciences, 2019, Apr-03, Volume: 20, Issue:7 Topics: Animals; C-Peptide; Caspase 3; Cell Death; Cell Line; Cell Shape; Cell Survival; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Muscle, Skeletal; Muscular Diseases; Myoblasts; Proto-Oncogene Proteins c-akt; Rats; Reactive Oxygen Species; Signal Transduction; Simvastatin	2019
A pilot study on the association between Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, 2019, Volume: 24, Issue:7 Topics: Adult; Dyslipidemias; Female; Humans; Incidence; Liver-Specific Organic Anion Transporter 1; Lovastatin; Malaysia; Male; Middle Aged; Muscular Diseases; Pilot Projects; Polymorphism, Genetic; Prospective Studies; Risk Factors; Simvastatin	2019
Montelukast modifies simvastatin-induced myopathy and hepatotoxicity. Drug development research, 2019, Volume: 80, Issue:7 Topics: Acetates; Albumins; Animals; Bilirubin; Chemical and Drug Induced Liver Injury; Creatine Kinase; Cyclopropanes; Drug Interactions; Globulins; Liver Function Tests; Male; Muscular Diseases; Myoglobin; Quinolines; Rats; Simvastatin; Sulfides	2019
Should anyone still be taking simvastatin 80 mg? BMJ case reports, 2013, Aug-08, Volume: 2013 Topics: Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Muscular Diseases; Rhabdomyolysis; Simvastatin	2013
A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature, 2013, Oct-17, Volume: 502, Issue:7471 Topics: Amidinotransferases; Cell Line; Cholesterol; Gene Expression Regulation; Gene Knockdown Techniques; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lymphocytes; Muscular Diseases; Polymorphism, Single Nucleotide; Quantitative Trait Loci; Simvastatin; Sterol Regulatory Element Binding Proteins; Transcription, Genetic	2013
Structural and functional characterization of simvastatin-induced myotoxicity in different skeletal muscles. Biochimica et biophysica acta, 2014, Volume: 1840, Issue:1 Topics: Animals; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ion Channels; Male; Muscle Contraction; Muscle Fibers, Fast-Twitch; Muscle Fibers, Slow-Twitch; Muscle, Skeletal; Muscular Diseases; Rats; Rats, Wistar; Simvastatin; Spectroscopy, Fourier Transform Infrared	2014
Effect of simvastatin-amiodarone drug interaction alert on appropriate prescribing. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2013, Nov-01, Volume: 70, Issue:21 Topics: Amiodarone; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Practice Patterns, Physicians'; Rhabdomyolysis; Simvastatin; United States; United States Food and Drug Administration	2013
Increased autophagy accelerates colchicine-induced muscle toxicity. Autophagy, 2013, Volume: 9, Issue:12 Topics: Animals; Autophagy; Colchicine; Disease Progression; Humans; Lysosomal Storage Diseases; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Muscular Diseases; Phagosomes; Simvastatin; Up-Regulation; Vacuoles	2013
Does reduced creatine synthesis protect against statin myopathy? Cell metabolism, 2013, Dec-03, Volume: 18, Issue:6 Topics: Amidinotransferases; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Quantitative Trait Loci; Simvastatin	2013
Expression quantitative trait locus analysis identifies novel genes for statin myopathy. Circulation. Cardiovascular genetics, 2014, Volume: 7, Issue:2 Topics: Amidinotransferases; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Quantitative Trait Loci; Simvastatin	2014
Low vitamin D as a risk factor for the development of myalgia in patients taking high-dose simvastatin: a retrospective review. Clinical therapeutics, 2014, Volume: 36, Issue:5 Topics: Adult; Aged; Dose-Response Relationship, Drug; Humans; Logistic Models; Male; Medical Records; Middle Aged; Muscular Diseases; Myalgia; Retrospective Studies; Rhabdomyolysis; Risk Factors; Simvastatin; Vitamin D; Vitamin D Deficiency; Young Adult	2014
The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clinical pharmacology and therapeutics, 2014, Volume: 96, Issue:4 Topics: Drug Interactions; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Muscular Diseases; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Genetic; Simvastatin	2014
GATM locus does not replicate in rhabdomyolysis study. Nature, 2014, Sep-18, Volume: 513, Issue:7518 Topics: Amidinotransferases; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Quantitative Trait Loci; Simvastatin	2014
GATM gene variants and statin myopathy risk. Nature, 2014, Sep-18, Volume: 513, Issue:7518 Topics: Amidinotransferases; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Quantitative Trait Loci; Simvastatin	2014
Mangravite et al. reply. Nature, 2014, Sep-18, Volume: 513, Issue:7518 Topics: Amidinotransferases; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Quantitative Trait Loci; Simvastatin	2014
[Myopathy and rhabdomyolysis after treatment with simvastatin, amlodipine, and roxithromycin]. Ugeskrift for laeger, 2014, Oct-06, Volume: 176, Issue:41 Topics: Aged; Amlodipine; Anti-Bacterial Agents; Antihypertensive Agents; Drug Interactions; Humans; Hypertension; Male; Muscular Diseases; Rhabdomyolysis; Roxithromycin; Simvastatin	2014
Simvastatin prescribing patterns before and after FDA dosing restrictions: a retrospective analysis of a large healthcare claims database. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2015, Volume: 15, Issue:1 Topics: Amlodipine; Calcium Channel Blockers; Comorbidity; Drug Interactions; Drug Labeling; Drug Prescriptions; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Incidence; Insurance, Health; Male; Middle Aged; Muscular Diseases; Off-Label Use; Pharmacovigilance; Practice Patterns, Physicians'; Retrospective Studies; Risk Factors; Simvastatin; United States; United States Food and Drug Administration	2015
Myopathy during treatment with the antianginal drug ranolazine. Journal of the neurological sciences, 2014, Dec-15, Volume: 347, Issue:1-2 Topics: Acetanilides; Angina Pectoris; Anticholesteremic Agents; Biopsy; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Middle Aged; Muscular Diseases; Piperazines; Ranolazine; Simvastatin; Treatment Outcome	2014
Inhibition of prenyltransferase activity by statins in both liver and muscle cell lines is not causative of cytotoxicity. Toxicology, 2015, Mar-02, Volume: 329 Topics: Alkyl and Aryl Transferases; Cell Line, Tumor; Dimethylallyltranstransferase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Membrane Proteins; Mevalonic Acid; Muscle, Skeletal; Muscular Diseases; Prenylation; Protein Processing, Post-Translational; rap1 GTP-Binding Proteins; Simvastatin	2015
[Clinical analysis of 160 cases of statin-induced myopathy]. Zhonghua xin xue guan bing za zhi, 2014, Volume: 42, Issue:11 Topics: Aged; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Myositis; Rhabdomyolysis; Simvastatin	2014
The AKT/mTOR signaling pathway plays a key role in statin-induced myotoxicity. Biochimica et biophysica acta, 2015, Volume: 1853, Issue:8 Topics: Animals; Apoptosis; Cells, Cultured; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred C57BL; Muscle Fibers, Skeletal; Muscle, Skeletal; Muscular Diseases; Proto-Oncogene Proteins c-akt; Signal Transduction; Simvastatin; TOR Serine-Threonine Kinases	2015
SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population. Medical science monitor : international medical journal of experimental and clinical research, 2015, May-20, Volume: 21 Topics: Aged; Atorvastatin; Czech Republic; Diabetes Mellitus; Dose-Response Relationship, Drug; Dyslipidemias; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Models, Genetic; Muscular Diseases; Myalgia; Obesity; Organic Anion Transporters; Polymorphism, Single Nucleotide; Simvastatin; Smoking	2015
Patient with statin-associated immune-mediated necrotizing myopathy presenting with subcutaneous edema, persistent bulbar weakness and absent anti-HMGCR. International journal of rheumatic diseases, 2017, Volume: 20, Issue:12 Topics: Aged; Autoantibodies; Azathioprine; Biopsy; Bulbar Palsy, Progressive; Edema; Glucocorticoids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Male; Muscle Weakness; Muscle, Skeletal; Muscular Diseases; Necrosis; Prednisolone; Recovery of Function; Simvastatin; Treatment Outcome	2017
The protective effect of Herba Cistanches on statin-induced myotoxicity in vitro. Journal of ethnopharmacology, 2016, Aug-22, Volume: 190 Topics: Adenosine Triphosphate; Animals; Apoptosis; Caspase 3; Cell Line; Chromatography, Liquid; Cistanche; Cytoprotection; Dose-Response Relationship, Drug; Glucosides; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle Fibers, Skeletal; Muscular Diseases; Phenols; Phytotherapy; Plant Extracts; Plants, Medicinal; Protective Agents; Rats; Simvastatin	2016
Simvastatin monotherapy as a potential option for statin-associated muscle symptoms: a case report. Journal of clinical pharmacy and therapeutics, 2016, Volume: 41, Issue:5 Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Simvastatin	2016
Hyperlipidaemia alone and in combination with acidosis can increase the incidence and severity of statin-induced myotoxicity. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2017, Mar-30, Volume: 100 Topics: Acidosis; Adult; Animals; Cell Line; Chylomicron Remnants; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins; Male; Mice; Models, Biological; Muscular Diseases; Pravastatin; Simvastatin	2017
Impairment of Energy-Dependent Processes in the Muscle Tissue as a Pathogenetic Mechanism of Statin-Induced Myopathy. Bulletin of experimental biology and medicine, 2017, Volume: 162, Issue:4 Topics: Animals; Animals, Outbred Strains; Anticholesteremic Agents; Electron Transport; Electron Transport Complex IV; Male; Mitochondria; Muscle Contraction; Muscle, Skeletal; Muscular Diseases; Oxidative Phosphorylation; Rats; Simvastatin; Superoxide Dismutase	2017
Laparoscopic partial nephrectomy in a patient on simvastatin : Delayed recovery from neuromuscular blockade. Der Anaesthesist, 2017, Volume: 66, Issue:6 Topics: Androstanols; Anesthesia; Delayed Emergence from Anesthesia; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Laparoscopy; Middle Aged; Muscular Diseases; Nephrectomy; Neuromuscular Blockade; Neuromuscular Nondepolarizing Agents; Postoperative Complications; Rocuronium; Simvastatin	2017
[Creatine kinase increase under simvastatin--therapeutic consequences?]. Medizinische Monatsschrift fur Pharmazeuten, 2008, Volume: 31, Issue:1 Topics: Biomarkers; Creatine Kinase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Simvastatin	2008
Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors. Drug safety, 2008, Volume: 31, Issue:7 Topics: Adult; Aged; Atorvastatin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Muscular Diseases; Pyrroles; Risk Management; Simvastatin	2008
Pharmacogenomics and drug toxicity. The New England journal of medicine, 2008, Aug-21, Volume: 359, Issue:8 Topics: Drug-Related Side Effects and Adverse Reactions; Genetic Markers; Genetic Predisposition to Disease; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Muscular Diseases; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Single Nucleotide; Rhabdomyolysis; Simvastatin	2008
[Bilateral leg compartment syndrome due to severe myonecrosis caused by inappropriate use of simvastatin]. Journal des maladies vasculaires, 2008, Volume: 33, Issue:4-5 Topics: Adult; Alanine Transaminase; Anterior Compartment Syndrome; Aspartate Aminotransferases; C-Reactive Protein; Creatinine; Female; Fibula; Functional Laterality; Humans; Ischemia; Leg; Muscle, Skeletal; Muscular Diseases; Myoglobin; Myoglobinuria; Simvastatin; Tibia; Tomography, X-Ray Computed; Treatment Outcome	2008
Interpretation of creatine kinase and aldolase for statin-induced myopathy: Reliance on serial testing based on biological variation. Clinica chimica acta; international journal of clinical chemistry, 2009, Volume: 399, Issue:1-2 Topics: Adult; Algorithms; Anticholesteremic Agents; Clinical Enzyme Tests; Creatine Kinase; Creatinine; Female; Fructose-Bisphosphate Aldolase; Glomerular Filtration Rate; Humans; Male; Middle Aged; Monitoring, Physiologic; Muscular Diseases; Natriuretic Peptide, Brain; Reference Values; Simvastatin; Time Factors	2009
Drug interactions with simvastatin. The Medical letter on drugs and therapeutics, 2008, Oct-20, Volume: 50, Issue:1297 Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Beverages; Citrus paradisi; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Food-Drug Interactions; Herb-Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Muscular Diseases; Organic Anion Transporters; Simvastatin; Tea	2008
Two cases of statin-induced myopathy caused by induced hypothyroidism. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2008, Volume: 14, Issue:6 Topics: Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypothyroidism; Iodine Radioisotopes; Male; Middle Aged; Muscular Diseases; Simvastatin; Thyroid Neoplasms; Thyroxine	2008
Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy. The Journal of physiology, 2009, Jan-15, Volume: 587, Issue:1 Topics: Animals; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle Fibers, Fast-Twitch; Muscular Diseases; Muscular Disorders, Atrophic; Nerve Tissue Proteins; Phosphorylation; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Signal Transduction; Simvastatin; Transcriptional Activation	2009
A case of asymptomatic cytoplasmic body myopathy revealed by sinvastatin. Neuromuscular disorders : NMD, 2009, Volume: 19, Issue:1 Topics: Aged; Biopsy; Creatine Kinase; Cytoplasm; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inclusion Bodies; Male; Muscle Weakness; Muscle, Skeletal; Muscular Diseases; Necrosis; Pain; Pyrimidines; Rhabdomyolysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2009
SLCO1B1 variants and statin-induced myopathy. The New England journal of medicine, 2009, Jan-15, Volume: 360, Issue:3 Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Muscular Diseases; Mutation; Organic Anion Transporters; Polymorphism, Single Nucleotide; Risk; Simvastatin	2009
Researchers worry about myopathy risk for patients taking high-dose simvastatin. JAMA, 2009, Jan-21, Volume: 301, Issue:3 Topics: Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Muscular Diseases; Organic Anion Transporters; Rhabdomyolysis; Risk; Simvastatin	2009
[Statin therapy and muscle disorders]. Orvosi hetilap, 2009, Feb-08, Volume: 150, Issue:6 Topics: Atorvastatin; Biological Availability; Cytochrome P-450 Enzyme System; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Skeletal; Muscular Diseases; Pravastatin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2009
Statin-induced myopathy in the rat: relationship between systemic exposure, muscle exposure and myopathy. Xenobiotica; the fate of foreign compounds in biological systems, 2009, Volume: 39, Issue:1 Topics: Animals; Disease Models, Animal; Female; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Muscle, Skeletal; Muscular Diseases; Pyridines; Pyrimidines; Rats; Rats, Wistar; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2009
Low dose simvastatin induces compositional, structural and dynamic changes in rat skeletal extensor digitorum longus muscle tissue. Bioscience reports, 2009, Oct-06, Volume: 30, Issue:1 Topics: Animals; Dose-Response Relationship, Drug; Down-Regulation; Fourier Analysis; Glycogen; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Male; Muscle Proteins; Muscle, Skeletal; Muscular Diseases; Nucleic Acids; Protein Denaturation; Protein Stability; Protein Structure, Secondary; Rats; Rats, Wistar; Simvastatin; Spectrophotometry, Infrared	2009
Decreased ubiquinone availability and impaired mitochondrial cytochrome oxidase activity associated with statin treatment. Toxicology mechanisms and methods, 2009, Volume: 19, Issue:1 Topics: Aged; Animals; Astrocytes; Cells, Cultured; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Electron Transport Complex IV; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Itraconazole; Male; Middle Aged; Muscle, Skeletal; Muscular Diseases; Rats; Rhabdomyolysis; Simvastatin; Ubiquinone	2009
[Myopathy in the course of hypolipemic theraphy in patient undergoing early cardiac rehabilitation after the percutaneous coronary intervention--a case report]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2009, Volume: 27, Issue:159 Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Female; Humans; Hypolipidemic Agents; Middle Aged; Muscular Diseases; Simvastatin	2009
Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy. Biochemical pharmacology, 2010, Apr-15, Volume: 79, Issue:8 Topics: Cells, Cultured; Cholesterol; Glycosylation; Hep G2 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle Fibers, Skeletal; Muscular Diseases; Protein Prenylation; Receptors, LDL; RNA, Messenger; Simvastatin; Sterol Regulatory Element Binding Protein 2; Ubiquinone	2010
On call. I'm a 61-year-old man with high blood pressure. My doctor wants me to take Zocor to lower my cholesterol, but I'm worried about muscle damage. I found a Web site that claimed coenyzme Q(10) would help. Is that right? Harvard men's health watch, 2010, Volume: 14, Issue:11 Topics: Anticholesteremic Agents; Health Knowledge, Attitudes, Practice; Humans; Male; Middle Aged; Mitochondria; Muscular Diseases; Simvastatin; Ubiquinone; Vitamins	2010
Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center. Journal of managed care pharmacy : JMCP, 2010, Volume: 16, Issue:7 Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Drug Interactions; Drug Labeling; Female; Follow-Up Studies; Hospitals, Veterans; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Muscular Diseases; Practice Patterns, Physicians'; Quality Assurance, Health Care; Retrospective Studies; Rhabdomyolysis; Risk Factors; Simvastatin; United States; United States Food and Drug Administration	2010
[High dose of simvastatin to minimize the risk of myopathy?]. Medizinische Monatsschrift fur Pharmazeuten, 2010, Volume: 33, Issue:9 Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Rhabdomyolysis; Simvastatin	2010
Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. The pharmacogenomics journal, 2012, Volume: 12, Issue:3 Topics: Adult; Aged; Atorvastatin; British Columbia; Case-Control Studies; Chi-Square Distribution; Female; Gene Frequency; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Netherlands; Odds Ratio; Organic Anion Transporters; Phenotype; Polymorphism, Single Nucleotide; Pyrroles; Risk Assessment; Risk Factors; Severity of Illness Index; Simvastatin	2012
On call. I've been taking Zocor since my heart attack in 2006. My cholesterol count has come way down, and I haven't had any heart problems. In the past few months, however, I've had some muscle aches. My blood tests don't show any muscle damage, but Harvard men's health watch, 2010, Volume: 15, Issue:3 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Drug Administration Schedule; Health Knowledge, Attitudes, Practice; Humans; Muscular Diseases; Risk Factors; Simvastatin	2010
Simvastatin-induced myopathy, the role of interaction with diltiazem and genetic predisposition. Journal of clinical pharmacy and therapeutics, 2011, Volume: 36, Issue:3 Topics: Aged, 80 and over; Antihypertensive Agents; Biotransformation; Cytochrome P-450 CYP3A; Diltiazem; Drug Interactions; Female; Hong Kong; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Middle Aged; Muscular Diseases; Polymorphism, Genetic; Simvastatin; Treatment Outcome	2011
Weighing the benefits of high-dose simvastatin against the risk of myopathy. The New England journal of medicine, 2011, Jul-28, Volume: 365, Issue:4 Topics: Anticholesteremic Agents; Creatine Kinase; Drug Approval; Drug Interactions; Drug Labeling; Dyslipidemias; Humans; Muscular Diseases; Risk; Simvastatin; United States; United States Food and Drug Administration	2011
Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge. Cardiovascular therapeutics, 2012, Volume: 30, Issue:5 Topics: Adult; Aged; Anticholesteremic Agents; Creatine Kinase; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Male; Middle Aged; Muscular Diseases; Retrospective Studies; Risk Factors; Sex Factors; Simvastatin	2012
Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes. Free radical biology & medicine, 2012, Jan-01, Volume: 52, Issue:1 Topics: Adenosine Diphosphate; Anticholesteremic Agents; Apoptosis; Cell Differentiation; Cell Respiration; Dose-Response Relationship, Drug; Electron Transport Complex I; Gene Expression; Humans; Hydrogen Peroxide; Mitochondria; Muscle Fibers, Skeletal; Muscular Diseases; Myoblasts; Oxidative Stress; Oxygen Consumption; Primary Cell Culture; Proto-Oncogene Proteins c-bcl-2; Respiratory System Agents; Signal Transduction; Simvastatin; Superoxides	2012
Simvastatin-induced myopathy with concomitant use of cyclosporine: case report. International journal of clinical pharmacology and therapeutics, 2011, Volume: 49, Issue:12 Topics: Cyclosporine; Cytochrome P-450 CYP3A; Drug Interactions; Female; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Transplantation; Liver-Specific Organic Anion Transporter 1; Middle Aged; Muscular Diseases; Organic Anion Transporters; Simvastatin	2011
Case records of the Massachusetts General Hospital. Case 7-2012. A 79-year-old man with pain and weakness in the legs. The New England journal of medicine, 2012, Mar-08, Volume: 366, Issue:10 Topics: Aged; Diabetes Complications; Diagnosis, Differential; Electromyography; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ileus; Leg; Male; Muscle Weakness; Muscular Diseases; Pain; Physical Examination; Quadriceps Muscle; Radiography, Abdominal; Rhabdomyolysis; Simvastatin	2012
Statin therapy, myopathy and exercise--a case report. Lipids in health and disease, 2012, Mar-16, Volume: 11 Topics: Adult; Dyslipidemias; Exercise; Humans; Hypolipidemic Agents; Male; Muscular Diseases; Physical Exertion; Simvastatin	2012
Use of administrative data to estimate the incidence of statin-related rhabdomyolysis. JAMA, 2012, Apr-18, Volume: 307, Issue:15 Topics: Adverse Drug Reaction Reporting Systems; Dose-Response Relationship, Drug; Electronic Health Records; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; International Classification of Diseases; Muscular Diseases; Pharmacies; Rhabdomyolysis; Risk; Sensitivity and Specificity; Simvastatin	2012
The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clinical pharmacology and therapeutics, 2012, Volume: 92, Issue:1 Topics: Drug Prescriptions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Muscular Diseases; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Single Nucleotide; Precision Medicine; Risk Assessment; Risk Factors; Simvastatin	2012
Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia. Pharmacogenetics and genomics, 2012, Volume: 22, Issue:11 Topics: Adult; Aged; Anticholesteremic Agents; Asian People; Cholesterol, LDL; Female; Fluorobenzenes; Genetic Variation; Humans; Hyperlipidemias; Introns; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Organic Anion Transporters; Polymorphism, Single Nucleotide; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2012
Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. PLoS computational biology, 2012, Volume: 8, Issue:8 Topics: Alprazolam; Databases, Factual; Drug Interactions; Duloxetine Hydrochloride; Electronic Health Records; Humans; Indoles; Loratadine; Muscular Diseases; Promethazine; Simvastatin; Thiophenes	2012
Myopathy and possible intestinal dysfunction in a patient treated with colchicine and simvastatin. The Medical journal of Australia, 2012, Sep-17, Volume: 197, Issue:6 Topics: Aged, 80 and over; Colchicine; Drug Interactions; Humans; Intestinal Pseudo-Obstruction; Male; Muscular Diseases; Simvastatin	2012
Effect of simvastatin on passive strain-induced skeletal muscle injury in rats. Muscle & nerve, 2012, Volume: 46, Issue:6 Topics: Analysis of Variance; Animals; C-Reactive Protein; Creatine Kinase; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Muscle, Skeletal; Muscular Diseases; Rats; Rats, Wistar; Simvastatin; Stress, Mechanical	2012
Pharmacological activation of the pyruvate dehydrogenase complex reduces statin-mediated upregulation of FOXO gene targets and protects against statin myopathy in rodents. The Journal of physiology, 2012, Dec-15, Volume: 590, Issue:24 Topics: Acetylcarnitine; Animals; Body Weight; Carbohydrate Metabolism; Cathepsin L; Cytoprotection; Dichloroacetic Acid; Disease Models, Animal; Dose-Response Relationship, Drug; Eating; Enzyme Activation; Enzyme Activators; Female; Forkhead Transcription Factors; Gene Expression Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle Proteins; Muscle, Skeletal; Muscular Diseases; Necrosis; Oxidation-Reduction; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Pyruvate Dehydrogenase Complex; Rats; Rats, Wistar; RNA, Messenger; Simvastatin; SKP Cullin F-Box Protein Ligases; Time Factors	2012
Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability. Drug metabolism and drug interactions, 2013, Volume: 28, Issue:1 Topics: Adult; Aged; Anti-Bacterial Agents; Creatine Kinase; Daptomycin; Drug Interactions; Female; Fluorobenzenes; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Pyrimidines; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Young Adult	2013
The HMG Co-A reductase inhibitors ('statins') and myotoxic effects. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2002, Volume: 92, Issue:8 Topics: Atorvastatin; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Muscular Diseases; Myositis; Pravastatin; Pyrroles; Rhabdomyolysis; Simvastatin	2002
Summaries for patients. Muscle abnormalities in four patients taking statins to treat unfavorable cholesterol levels. Annals of internal medicine, 2002, Oct-01, Volume: 137, Issue:7 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biopsy; Creatine Kinase; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Muscular Diseases; Pain; Pyrroles; Simvastatin	2002
Low-density lipoprotein lowering therapy: an analysis of the options. Journal of the American College of Cardiology, 2002, Dec-18, Volume: 40, Issue:12 Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Disease; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Muscular Diseases; Simvastatin	2002
[Generalized muscle pain in a 67-year-old patient. Myalgia/myositis in therapy with Zocor]. Praxis, 2003, May-14, Volume: 92, Issue:20 Topics: Aged; Anticholesteremic Agents; Creatine Kinase; Diagnosis, Differential; Emergencies; Female; Humans; Metabolic Syndrome; Muscular Diseases; Pain; Polymyositis; Rhabdomyolysis; Simvastatin	2003
Cytoskeletal myotoxicity from simvastatin and colchicine. Muscle & nerve, 2004, Volume: 30, Issue:6 Topics: Aged; Colchicine; Cytoskeleton; Humans; Male; Muscular Diseases; Rhabdomyolysis; Simvastatin	2004
Statin-associated exacerbation of myasthenia gravis. Neurology, 2004, Dec-14, Volume: 63, Issue:11 Topics: Atorvastatin; Cytokines; Dysarthria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Lovastatin; Male; Middle Aged; Mitochondria; Models, Neurological; Muscular Diseases; Myasthenia Gravis; Neural Conduction; Pravastatin; Pyridostigmine Bromide; Pyrroles; Simvastatin; Th2 Cells; Ubiquinone	2004
Statin-disclosed acid maltase deficiency. Journal of internal medicine, 2005, Volume: 258, Issue:2 Topics: Adult; Anticholesteremic Agents; Glycogen Storage Disease Type II; Humans; Hypercholesterolemia; Male; Muscular Diseases; Rhabdomyolysis; Simvastatin	2005
Statin-associated myopathy with normal creatine kinase levels. Case report from a Norwegian family. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2005, Volume: 113, Issue:9 Topics: Adult; Creatine Kinase; Female; Humans; Male; Muscle Cramp; Muscle Weakness; Muscle, Skeletal; Muscular Diseases; Norway; Simvastatin	2005
Muscle symptoms associated with statins: a series of twenty patients. Basic & clinical pharmacology & toxicology, 2006, Volume: 98, Issue:1 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Creatine Kinase; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Pravastatin; Pyrroles; Simvastatin	2006
Sporadic rippling muscle disease unmasked by simvastatin. Muscle & nerve, 2006, Volume: 34, Issue:4 Topics: Anticholesteremic Agents; Calcium; Caveolin 3; Dysferlin; Homeostasis; Humans; Hypercholesterolemia; Male; Membrane Proteins; Middle Aged; Muscle Contraction; Muscle Proteins; Muscle, Skeletal; Muscular Diseases; Myasthenia Gravis; Simvastatin	2006
Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscular disorders : NMD, 2007, Volume: 17, Issue:2 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Atorvastatin; Creatine Kinase; Female; Folic Acid Antagonists; Genes, MHC Class I; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Methotrexate; Middle Aged; Mitochondria, Muscle; Muscle Weakness; Muscular Diseases; Prednisolone; Pyrroles; Sarcolemma; Simvastatin; Up-Regulation	2007
Myopathy associated with atorvastatin-ezetimibe combination therapy. Pharmacotherapy, 2007, Volume: 27, Issue:2 Topics: Aged; Azetidines; Creatine Kinase; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Humans; Hypercholesterolemia; Male; Muscular Diseases; Simvastatin	2007
Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacological research, 2007, Volume: 55, Issue:4 Topics: Aged; Aged, 80 and over; Apolipoproteins E; Aryl Hydrocarbon Hydroxylases; Case-Control Studies; Cholesterol; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gene Frequency; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Male; Middle Aged; Muscular Diseases; Phenotype; Polymorphism, Genetic; Risk Factors; Simvastatin; Treatment Outcome	2007
Fatal and widespread skeletal myopathy confirmed morphologically years after initiation of simvastatin therapy. The American journal of cardiology, 2007, Apr-15, Volume: 99, Issue:8 Topics: Calcinosis; Deglutition Disorders; Dysarthria; Dyspnea; Fatal Outcome; Fibrosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Muscle Fibers, Skeletal; Muscle Weakness; Muscular Diseases; Necrosis; Simvastatin	2007
Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle & nerve, 2007, Volume: 36, Issue:3 Topics: Aged; Aged, 80 and over; Atorvastatin; Female; Genomics; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Muscular Diseases; Pain; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Receptors, Serotonin; Simvastatin	2007
Myxoedema revealed by simvastatin induced myopathy. BMJ (Clinical research ed.), 1994, Feb-26, Volume: 308, Issue:6928 Topics: Adult; Anticholesteremic Agents; Humans; Hypercholesterolemia; Lovastatin; Male; Muscular Diseases; Myxedema; Simvastatin	1994
Biochemical diagnosis of myocardial infarction? Cardiac enzymes or caveat emptor. Postgraduate medical journal, 1994, Volume: 70, Issue:820 Topics: Creatine Kinase; Diagnosis, Differential; Humans; Lovastatin; Male; Middle Aged; Muscular Diseases; Myocardial Infarction; Simvastatin	1994
Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits. Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie, 1993, Volume: 193, Issue:5 Topics: Administration, Oral; Animals; Cholesterol; Creatine Kinase; Hydroxymethylglutaryl-CoA Reductase Inhibitors; L-Lactate Dehydrogenase; Lovastatin; Male; Muscles; Muscular Diseases; Pravastatin; Rabbits; Simvastatin; Ubiquinone	1993
Enhanced myopathy following administration of hypolipidemic agents under urethane anesthesia. Biological & pharmaceutical bulletin, 1997, Volume: 20, Issue:1 Topics: Anesthesia; Animals; Bezafibrate; Calcium; Creatine Kinase; Hypolipidemic Agents; Lovastatin; Male; Muscular Diseases; Pravastatin; Rats; Rats, Wistar; Simvastatin; Urethane	1997
Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. Southern medical journal, 1997, Volume: 90, Issue:5 Topics: Anticholesteremic Agents; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Middle Aged; Muscular Diseases; Rhabdomyolysis; Simvastatin	1997
Simvastatin-induced myopathy in a patient treated for hypercholesterolemia. Morphological aspects. Polish journal of pathology : official journal of the Polish Society of Pathologists, 1997, Volume: 48, Issue:1 Topics: Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Muscle, Skeletal; Muscular Diseases; Simvastatin	1997
Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study. Toxicology and applied pharmacology, 1998, Volume: 152, Issue:1 Topics: Animals; Cholesterol; Creatine Kinase; Electromyography; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Microscopy, Electron; Mitochondria, Muscle; Muscle Fibers, Skeletal; Muscle, Skeletal; Muscular Diseases; Myotonia; Necrosis; Phospholipids; Pravastatin; Rabbits; Simvastatin; Tissue Distribution; Ubiquinone	1998
Judicious evaluation of adverse drug reactions: inaccurate assessment of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced muscle injury. Pharmacotherapy, 1999, Volume: 19, Issue:2 Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Atorvastatin; Diagnostic Errors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Pyrroles; Rhabdomyolysis; Simvastatin	1999
The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia. Atherosclerosis, 1999, Volume: 143, Issue:1 Topics: Adult; Aged; Apolipoproteins E; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Genotype; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Muscular Diseases; Mutation; Receptors, LDL; Simvastatin; Tendons; Xanthomatosis	1999
Statin induced myopathy does not show up in MIBI scintigraphy. Nuclear medicine communications, 2001, Volume: 22, Issue:5 Topics: Adult; Anticholesteremic Agents; Atorvastatin; Breast Neoplasms; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lovastatin; Male; Middle Aged; Muscle, Skeletal; Muscular Diseases; Pain; Pravastatin; Pyridines; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Simvastatin; Technetium Tc 99m Sestamibi	2001
Hypothyroidism and simvastatin. Hong Kong medical journal = Xianggang yi xue za zhi, 2001, Volume: 7, Issue:2 Topics: Anticholesteremic Agents; Creatine Kinase; Humans; Hypothyroidism; Muscular Diseases; Simvastatin	2001
Myopathy secondary to simvastatin in a type 2 diabetic patient. The Journal of the Association of Physicians of India, 2002, Volume: 50 Topics: Anticholesteremic Agents; Diabetes Mellitus, Type 2; Humans; Hypercholesterolemia; Male; Middle Aged; Muscular Diseases; Simvastatin	2002
Experimental simvastatin-induced myopathy in rabbits. Journal of the neurological sciences, 1992, Volume: 113, Issue:1 Topics: Administration, Oral; Animals; Electromyography; Enzymes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lovastatin; Male; Muscles; Muscular Diseases; Rabbits; Simvastatin	1992
Myopathy associated with HMG-CoA reductase inhibitors (HMGRIs) and cyclosporin A: evaluation in a rat model. European heart journal, 1992, Volume: 13 Suppl B Topics: Animals; Anticholesteremic Agents; Cyclosporine; Drug Synergism; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscles; Muscular Diseases; Necrosis; Pravastatin; Rats; Rats, Inbred Strains; Simvastatin; Structure-Activity Relationship	1992
Pravastatin and simvastatin for hypercholesterolemia. The Medical letter on drugs and therapeutics, 1991, Mar-08, Volume: 33, Issue:839 Topics: Anticholesteremic Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypercholesterolemia; Lovastatin; Muscular Diseases; Naphthalenes; Pravastatin; Simvastatin	1991
HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. The Journal of pharmacology and experimental therapeutics, 1991, Volume: 257, Issue:3 Topics: Animals; Biliary Tract; Cholestasis; Cyclosporins; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Male; Microsomes, Liver; Muscular Diseases; Naphthalenes; Pravastatin; Rats; Rats, Inbred Strains; Simvastatin	1991
Cerebrotendinous xanthomatosis: treatments with simvastatin, lovastatin, and chenodeoxycholic acid in 3 siblings. Neurology, 1991, Volume: 41, Issue:3 Topics: Adult; Anticholesteremic Agents; Brain Diseases; Chenodeoxycholic Acid; Female; Humans; Lovastatin; Muscular Diseases; Simvastatin; Tendons; Tomography, X-Ray Computed; Xanthomatosis	1991
Muscle side effects associated with simvastatin therapy. The Medical journal of Australia, 1990, Nov-05, Volume: 153, Issue:9 Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Child; Female; Humans; Lovastatin; Male; Middle Aged; Mitochondria, Muscle; Muscular Diseases; Pain; Simvastatin	1990